DGAP-News: Izotropic submits IzoView commercial prototype and registers new patents

DGAP-News: Izotropic Corporation / Keyword(s): miscellaneous

Izotropic announces IzoView commercial prototype and new patent files

05/12/2022 / 22:53
The issuer / publisher is responsible for the content of the notification.

VANCOVER, BC – (Newsville Corp – Thursday, May 12, 2022) – Tuesday Izotropic company (Custom search engine: IZO) (OTCQB: IZOZF) (FSE: 1R3) (“isotropic“or that”company‘), a company that markets the IzoView (computed tomography) breast tomography platform for more accurate breast cancer detection and diagnosis, is pleased to submit a commercial prototype design for the device that will be used in upcoming clinical trials for market approval in the United States.

To view an improved version of this graphic, please visit:

Realistic and detailed 3D animation of IzoView’s design, functionality and capabilities is now available live on the company’s YouTube channel at the following link: https://youtu.be/k3hREjHtymk

IzoView has been updated and redesigned to offer the latest breast imaging device of the future. In recent months, user experience and its importance to patients, operators, insurance providers, and customers have been subject to further study. The company aims to achieve a design and function that will increase demand, acceptance and market uptake when a product is approved for sale.

The main feature of the IzoView design is the newly developed self-protection technology, in which the emitted radiation remains inside the device itself during shooting, protecting the operators and the surrounding area. In the company’s first self-shield design, only the patient’s imaged breast is exposed to radiation. IzoView can be operated safely even in rooms where the usual CT protective barriers and lead partitions to protect the operator and the environment from radiation are not always required.

The company has begun patenting the unique and important features of the IzoView mammography system. The company will co-own these patents with the University of California Board of Directors, through which Izotropic holds exclusive global license rights to CT breast implants, including ten additional patents and patent applications pending.

On behalf of the board of directors

Contact for investor relations:
James Berard
Email: [email protected]
Mobile: 778-228-2314
Toll Free: 1-833-IZOCORP extension 1

Contact for media inquiries:
Jacqueline Thast
Email: [email protected]
Toll Free: 1-833-IZOCORP extension 3

About Izotropic
Izotropic Corporation is the only public company to market a dedicated breast computed tomography (CT) platform, IzoView, for more accurate breast cancer detection and diagnosis. In order to give patients and providers faster access to the IzoView, Izotropic wants to demonstrate the superiority of diagnostic mammography tomography over diagnostic mammography procedures in the first clinical study. In clinical follow-up studies, isotropic will validate platform applications including mammography, treatment planning and monitoring in surgical oncology, and breast reconstruction and implant monitoring in plastic and reconstructive surgery.

Additional information about Izotropic can be found on its website at izocorp.com and on its SEDAR profile at sedar.com.

forward-looking statements
This document may contain “forward-looking statements” that are based on current estimates, assumptions, forecasts and expectations of management and business, the Company’s knowledge of the market and the relevant economic environment. The company has attempted to use terms such as “expect,” “believe,” “imagin,” “estimate,” “expect,” “intend,” “may,” “plan,” “expect,” “project,” “aim,” Possible “,” will “,” will “,” can “,” should “,” continue “,” consider “and other similar expressions and derivatives. However, not all forward-looking statements contain these identifying words. These statements are not guarantees of performance and involve risks and uncertainties that are difficult to control or predict. This may cause future results of the Company’s business activities to differ materially from the content and effects of such statements. Forward-looking statements speak only as of the date they are made. The Company undertakes no obligation to update or revise any forward-looking statements to reflect new information or the occurrence of future events or conditions, except as required by law. Neither the Company nor any of its shareholders, officers or advisors shall be liable for any action or results of any action taken by any person based on the information contained herein, including but not limited to the purchase or sale of securities of the Company. Nothing in this document should be construed as medical or other advice of any kind. All images are for illustration purposes only. IzoView is not yet available for sale.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/123867


Click or paste the following link in your web browser to view the linked documents http://www.newsfilecorp.com/release/123867

News source: Newsfeed

05/12/2022 Publication of company news / financial news, transmitted by DGAP – one of the services of EQS Group AG.
The issuer / publisher is responsible for the content of the notification.

DGAP’s distribution services include legal reports, corporate/financial news, and press releases.
Media archive at http://www.dgap.de

Leave a Comment